PRA
REGN icon

Parametric Risk Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Parametric Risk Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$1.03M Sell
2,570
-2,030
-44% -$814K 0.07% 87
2016
Q2 		$1.61M Buy
+4,600
New +$1.77M 0.11% 96

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Parametric Risk Advisors's REGN Position: Q3 2016 in Review

Parametric Risk Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 44% in Q3 2016, selling an estimated $814K and leaving 2,570 shares worth $1.03M. The position accounts for 0.07% of the portfolio, ranked #87.

Parametric Risk Advisors first reported a position in REGN in Q2 2016 and has held it in 2 quarters since. The position peaked at $1.61M in Q2 2016. 553 funds tracked by Wall St. Rank hold REGN as of Q3 2016.

  • Parametric Risk Advisors held 2,570 shares of Regeneron Pharmaceuticals worth $1.03M as of Q3 2016.
  • Parametric Risk Advisors sold 2,030 Regeneron Pharmaceuticals shares in Q3 2016, an estimated $814K.
  • Regeneron Pharmaceuticals made up 0.07% of Parametric Risk Advisors's portfolio in Q3 2016, its #87 holding.
  • Parametric Risk Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2016 and has held it in 2 quarters since.
  • Parametric Risk Advisors's Regeneron Pharmaceuticals position peaked at $1.61M in Q2 2016.
  • 553 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2016.

Based on Parametric Risk Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.